title: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.
abstract: BACKGROUND
  After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse.
  
  
  METHODS
  We conducted a multicenter, randomized trial that compared fluconazole (200 mg per day given orally) with amphotericin B (1 mg per kilogram of body weight per week given intravenously) in patients with AIDS who had completed primary therapy for cryptococcal meningitis with amphotericin B (greater than or equal to 15 mg per kilogram). To be eligible, patients had to have at least two negative cultures of cerebrospinal fluid immediately before randomization. The primary end point was relapse of cryptococcal disease as confirmed by biopsy or culture.
  
  
  RESULTS
  Of 218 patients initially enrolled, 119 were assigned to fluconazole and 99 to amphotericin B. Twenty-three patients were found not to have met the entry criteria; six other patients assigned to amphotericin B did not receive it and were lost to follow-up. Of the remaining 189 patients, after a median follow-up of 286 days 14 of 78 receiving amphotericin B (18 percent) and 2 of 111 assigned to fluconazole (2 percent) had relapses of symptomatic cryptococcal disease (P less than 0.001 by Fisher's exact test). There was a difference of 19 percent in the estimated probability of remaining relapse-free at one year between the fluconazole group (97 percent) and the amphotericin B group (78 percent) (95 percent confidence interval, 7 percent to 31 percent; P less than 0.001). Serious drug-related toxicity was more frequent in the amphotericin B group (P = 0.02), as were bacterial infections (P = 0.004) and bacteremia (P = 0.002).
  
  
  CONCLUSIONS
  Fluconazole taken by mouth is superior to weekly intravenous therapy with amphotericin B to prevent relapse in patients with AIDS-associated cryptococcal meningitis after primary treatment with amphotericin B.
authors.affiliation: Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110.
authors.forename: W G
authors.initials: WG
authors.lastname: Powderly
authors.forename: M S
authors.initials: MS
authors.lastname: Saag
authors.forename: G A
authors.initials: GA
authors.lastname: Cloud
authors.forename: P
authors.initials: P
authors.lastname: Robinson
authors.forename: R D
authors.initials: RD
authors.lastname: Meyer
authors.forename: J M
authors.initials: JM
authors.lastname: Jacobson
authors.forename: J R
authors.initials: JR
authors.lastname: Graybill
authors.forename: A M
authors.initials: AM
authors.lastname: Sugar
authors.forename: V J
authors.initials: VJ
authors.lastname: McAuliffe
authors.forename: S E
authors.initials: SE
authors.lastname: Follansbee
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000284:Administration, Oral; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D016919:Meningitis, Cryptococcal / Q000188:drug therapy / Q000517:prevention & control*; D008875:Middle Aged; D015999:Multivariate Analysis; D012008:Recurrence
chemical_list: D000666:Amphotericin B; D015725:Fluconazole